Long-awaited Review of Lyme Disease Guidelines Set for Thursday
On Thursday, July 30, 2009, the Infectious Diseases Society of America (IDSA) Lyme Disease Review Panel will conduct a daylong hearing, required under an antitrust settlement between the IDSA and the Connecticut Attorney General. Patients, researchers and physicians from both sides of this hotly debated topic will present testimony to the panel in Washington, DC. The Attorney General’s investigation of the IDSA revealed the 2006 guidelines panel members had widespread commercial conflicts of interests and had excluded peer-reviewed scientific evidence supporting chronic Lyme disease. The new panel is charged with evaluating the scientific basis of the guidelines, which currently deny patients access to antibiotic therapy – the only treatment option available for chronic Lyme disease. Health insurers rely on the IDSA guidelines to deny medical reimbursements. State medical boards use them to launch unprofessional conduct actions, placing physicians who continue to treat chronic Lyme disease at risk of losing their licenses.
